Efficacy of reduced-dose regimen of a capsule containing bismuth subcitrate, metronidazole, and tetracycline given with amoxicillin and esomeprazole in the treatment of Helicobacter Pylori infection

被引:7
|
作者
Harb, Ali H. [1 ]
El Reda, Zeinab D. [1 ]
Sarkis, Fayez S. [1 ]
Chaar, Hani F. [1 ]
Sharara, Ala, I [1 ]
机构
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Gastroenterol, Beirut, Lebanon
关键词
Helicobacter pylori; eradication; adverse events; CLARITHROMYCIN;
D O I
10.1177/2050640614560787
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
It is well known that triple therapy for Helicobacter pylori is losing efficacy worldwide. A regimen containing proton pump inhibitor and multiple-dose capsules of bismuth, metronidazole, and tetracycline has proven efficacy. In addition, a literature review on dosage of previous regimens shows that half-dose clarithromycin-based regimens are equally effective to full-dose regimens. However, the applicability of dose reduction to bismuth-based therapy is unknown. This communication shows that a reduced-dose bismuth-based regimen fails to achieve acceptable eradication rates.
引用
收藏
页码:95 / 96
页数:2
相关论文
共 39 条
  • [31] Efficacy comparison of 7-and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial
    Oh, Chang Kyo
    Lim, Hyun
    Seo, Seung In
    Lee, Sang Pyo
    Bang, Chang Seok
    Shin, Woon Geon
    Kim, Jin Bae
    Jang, Hyun Joo
    Baik, Gwang Ho
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [32] Efficacy of 7-day high dose esomeprazole-based triple therapy versus 7-day standard dose non-esomeprazole-based triple therapy for first-line treatment of Helicobacter pylori infection
    Heo, Jae Joon
    Kim, Sung Eun
    Park, Moo In
    Park, Seun Ja
    Moon, Won
    Kim, Jae Hyun
    Jung, Kyoungwon
    Song, Jiyun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 91 - 91
  • [33] Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
    Xie, Yong
    Zhu, Zhenhua
    Wang, Jiangbin
    Zhang, Lingxia
    Zhang, Zhenyu
    Lu, Hong
    Zeng, Zhirong
    Chen, Shiyao
    Liu, Dongsheng
    Lv, Nonghua
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (09)
  • [34] A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies
    Gao, Wen
    Xu, Ying
    Liu, Jianxiang
    Wang, Xiaolei
    Dong, Xinhong
    Teng, Guigen
    Liu, Binbin
    Dong, Jinpei
    Ge, Chaoyi
    Ye, Hui
    Zhang, Xuezhi
    Cheng, Hong
    HELICOBACTER, 2023, 28 (02)
  • [35] Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection
    Lee, Young Dal
    Kim, Sung Eun
    Park, Seun Ja
    Park, Moo In
    Moon, Won
    Kim, Jae Hyun
    Jung, Kyoungwon
    Song, Jiyun
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2020, 76 (03) : 142 - 149
  • [36] The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naive Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial
    Tai, Wei-Chen
    Yang, Shih-Cheng
    Yao, Chih-Chien
    Wu, Cheng-Kun
    Liu, An-Che
    Lee, Chen-Hsiang
    Kuo, Yuan-Hung
    Chuah, Seng-Kee
    Liang, Chih-Ming
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (05) : 1415 - 1427
  • [37] Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial
    Ding, Yu-Ming
    Zhang, Qiu-Mei
    Li, Rui-Li
    Han, Zhong-Xue
    Zhao, Qing
    Xu, Li-Dong
    Wang, Ke-Yu
    Nan, Xue-Ping
    Duan, Miao
    Zeng, Shu-Yan
    Kong, Qing-Zhou
    Wang, Hui
    Wu, Xiao-Qi
    Zhang, Ning
    Li, Yan-Qing
    Zuo, Xiu-Li
    Li, Yue-Yue
    HELICOBACTER, 2024, 29 (04)
  • [38] 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial
    Liou, Jyh-Ming
    Chen, Chieh-Chang
    Fang, Yu-Jen
    Chen, Po-Yueh
    Chang, Chi-Yang
    Chou, Chu-Kuang
    Chen, Mei-Jyh
    Tseng, Cheng-Hao
    Lee, Ji-Yuh
    Yang, Tsung-Hua
    Chiu, Min-Chin
    Yu, Jian-Jyun
    Kuo, Chia-Chi
    Luo, Jiing-Chyuan
    Hsu, Wen-Feng
    Hu, Wen-Hao
    Tsai, Min-Horn
    Lin, Jaw-Town
    Shun, Chia-Tung
    Twu, Gary
    Lee, Yi-Chia
    Bair, Ming-Jong
    Wu, Ming-Shiang
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (09) : 2510 - 2518
  • [39] The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial
    Wei-Chen Tai
    Shih-Cheng Yang
    Chih-Chien Yao
    Cheng-Kun Wu
    An-Che Liu
    Chen-Hsiang Lee
    Yuan-Hung Kuo
    Seng-Kee Chuah
    Chih-Ming Liang
    Infectious Diseases and Therapy, 2023, 12 : 1415 - 1427